PTC Therapeutics (FRA:BH3) YoY EBITDA Growth : 76.23% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. PTC Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 76.23%.

PTC Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was €-0.39.

PTC Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for PTC Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics YoY EBITDA Growth Chart

PTC Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-76.84

-26.40

-22.55

-4.67

16.36

PTC Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial															-34.73	10.66	-50.04	6.32	76.23

PTC Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

PTC Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-4.048	-	-4.84)	/	\| -4.84 \|
=	16.36 %

PTC Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.39	-	-1.641)	/	\| -1.641 \|
=	76.23 %

PTC Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics (FRA:BH3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (FRA:BH3) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

PTCT:USA BH3:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

PTC Therapeutics (FRA:BH3) Headlines

No Headlines